Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded

被引：301
作者：
Cattaneo, Roberto [1 ]
Miest, Tanner [1 ]
Shashkova, Elena V. [2 ]
Barry, Michael A. [2 ,3 ]
机构：
[1] Mayo Clin, Dept Mol Med, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Immunol, Div Infect Dis, Translat Immunovirol & Biodef Program, Rochester, MN 55905 USA
来源：
NATURE REVIEWS MICROBIOLOGY | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1038/nrmicro1927
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.
引用
收藏
页码：529 / 540
页数：12
相关论文
共 119 条
[1]   A road map for those who don't know JAK-STAT [J].
Aaronson, DS ;
Horvath, CM .
SCIENCE, 2002, 296 (5573) :1653-1655
[2]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[3]   ADENOVIRUS PROTEINS FROM BOTH E1B READING FRAMES ARE REQUIRED FOR TRANSFORMATION OF RODENT CELLS BY VIRAL-INFECTION AND DNA TRANSFECTION [J].
BARKER, DD ;
BERK, AJ .
VIROLOGY, 1987, 156 (01) :107-121
[4]   Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity [J].
Barton, KN ;
Paielli, D ;
Zhang, Y ;
Koul, S ;
Brown, SL ;
Lu, M ;
Seely, J ;
Kim, JH ;
Freytag, SO .
MOLECULAR THERAPY, 2006, 13 (02) :347-356
[5]   Genetically targeted adenovirus vector directed to CD40-expressing cells [J].
Belousova, N ;
Korokhov, N ;
Krendelshchikova, V ;
Simonenko, V ;
Mikheeva, G ;
Triozzi, PL ;
Aldrich, WA ;
Banerjee, PT ;
Gillies, SD ;
Curiel, DT ;
Krasnykh, V .
JOURNAL OF VIROLOGY, 2003, 77 (21) :11367-11377
[6]   Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus [J].
Berk, AJ .
ONCOGENE, 2005, 24 (52) :7673-7685
[7]   An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].
Bischoff, JR ;
Kim, DH ;
Williams, A ;
Heise, C ;
Horn, S ;
Muna, M ;
Ng, L ;
Nye, JA ;
SampsonJohannes, A ;
Fattaey, A ;
McCormick, F .
SCIENCE, 1996, 274 (5286) :373-376
[8]  
BOVIATSIS EJ, 1994, CANCER RES, V54, P5745
[9]   An oncolytic measles virus engineered to enter cells through the CD20 antigen [J].
Bucheit, AD ;
Kumar, S ;
Grote, DM ;
Lin, YK ;
von Messling, V ;
Cattaneo, RB ;
Fielding, AK .
MOLECULAR THERAPY, 2003, 7 (01) :62-72
[10]   Current advances and future challenges in adenoviral vector biology and targeting [J].
Campos, Samuel K. ;
Barry, Michael A. .
CURRENT GENE THERAPY, 2007, 7 (03) :189-204
12345678910